Self-assembly of therapeutic agent-peptide nanostructures
Disclosed are conjugates of hydrophobic drugs linked to protected or unprotected amino acids or peptides. The disclosed conjugates are amphiphilic and can self assemble into nantubes. Nanotubes comprising the conjugates are also described and can have high loading of the drug and protect it from degradation or elimination. The nanotubes are well suited to deliver hydrophobic and unstable drugs to individuals.
1. A nanotube comprising a wall, wherein the wall comprises a plurality of conjugates of Formula II
where n is from 1 to 4,
each R 1 and R 2 are, independent of one another, H, OH, lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower haloalkenyl, lower haloalkynyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, phenyl, aryl, aryloxy, lower alkoxy, lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower alkylcarbonyl, lower carboxyester, lower carboxamido, cyano, hydrogen or deuterium, halogen, hydroxy, amino, lower alkylamino, arylamino, amido, nitro, thiol, lower alkylthio, lower haloalkylthio, lower perhaloalkylthio, arylthio, sulfonate, sulfonic acid, trisubstituted silyl, N 3 , SH, SCH 3 , C(O)CH 3 , CO 2 CH 3 , or CO 2 H, or together two R 1 or R 1 and R 2 can form a fused cycloalkyl or cycloheteroalkyl;
L is C(O)—(CH 2 ) m —C(O), where m is from 1 to 6;
AA is a protected or unprotected lysyl-lysyl or lysyl-phenylalanyl-lysyl-lysyl (SEQ ID NO:6); wherein L is bonded at a side chain of one of the lysyl residues of AA.
2. The nanotube of claim 1 , wherein the wall comprises a hydrophilic domain comprising the AA moiety of the conjugate and a hydrophobic domain comprising the
portion of the conjugate.
3. The nanotube of claim 1 , wherein the
portion of the conjugate is at least about 50 wt. % of the nanotube.
4. The nanotube of claim 1 , wherein the nanotube has a zeta potential of about zero mV.
5. The nanotube of claim 1 , wherein AA is protected at the N terminus or an amino acid residue side chain with a benzoyloxycarbonyl, tert-butoxycarbonyl, acetate, trifluoroacetate, 9-fluorenylmethyloxycarbonyl, or 2-bromobenzyloxycarbonyl, or N-hydroxysuccinimide.
6. The nanotube of claim 1 , wherein AA is unprotected lysyl-lysyl, or unprotected lysyl-phenylalanyl-lysyl-lysyl (SEQ ID NO:6), and the linker moiety is C 1 -C 6 alkyldiester.
7. The nanotube of claim 1 , wherein the conjugate has Formula II-A, II-B, II-C, II-D, or II-E: